Trastuzumab deruxtecan in the treatment of adult patients with HER2-positive breast cancer

IF 0.3 Q4 ONCOLOGY Oncology in Clinical Practice Pub Date : 2023-10-27 DOI:10.5603/ocp.97612
Joanna Kufel-Grabowska
{"title":"Trastuzumab deruxtecan in the treatment of adult patients with HER2-positive breast cancer","authors":"Joanna Kufel-Grabowska","doi":"10.5603/ocp.97612","DOIUrl":null,"url":null,"abstract":"In 2020, approximately 18,000 women in Poland were diagnosed with breast cancer, and 6,000 of them died. In recent years, we have witnessed significant progress in the diagnosis and treatment of breast cancer patients. When detected early and treated appropriately, the prognosis is very good, and even some patients with distant metastases have experienced long-term survival. The most common biological subtype is hormone receptor-positive breast cancer, accounting for about 70% of diagnoses, showing expression of estrogen and progesterone receptors. Triple-negative breast cancer and HER2-positive breast cancer each make up approximately 15% of all cases. In the treatment of advanced HER2-positive breast cancer, a combination of docetaxel with pertuzumab and trastuzumab is used in the first line. In subsequent lines of treatment, options include trastuzumab deruxtecan (T-DXd), trastuzumab emtansine, lapatinib, tucatinib, margetuximab, and trastuzumab. Trastuzumab derukstekan is an immunoconjugate that, upon entering the cell, releases a cytostatic agent that destroys its genetic material and neighboring cells (the “bystander effect”). It significantly prolongs the time to disease progression and overall survival compared to standard treatments used in the second and subsequent lines of treatment. It represents an effective and valuable therapeutic option for patients with early-stage HER2- positive metastatic breast cancer.","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"23 1","pages":"0"},"PeriodicalIF":0.3000,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology in Clinical Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/ocp.97612","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

In 2020, approximately 18,000 women in Poland were diagnosed with breast cancer, and 6,000 of them died. In recent years, we have witnessed significant progress in the diagnosis and treatment of breast cancer patients. When detected early and treated appropriately, the prognosis is very good, and even some patients with distant metastases have experienced long-term survival. The most common biological subtype is hormone receptor-positive breast cancer, accounting for about 70% of diagnoses, showing expression of estrogen and progesterone receptors. Triple-negative breast cancer and HER2-positive breast cancer each make up approximately 15% of all cases. In the treatment of advanced HER2-positive breast cancer, a combination of docetaxel with pertuzumab and trastuzumab is used in the first line. In subsequent lines of treatment, options include trastuzumab deruxtecan (T-DXd), trastuzumab emtansine, lapatinib, tucatinib, margetuximab, and trastuzumab. Trastuzumab derukstekan is an immunoconjugate that, upon entering the cell, releases a cytostatic agent that destroys its genetic material and neighboring cells (the “bystander effect”). It significantly prolongs the time to disease progression and overall survival compared to standard treatments used in the second and subsequent lines of treatment. It represents an effective and valuable therapeutic option for patients with early-stage HER2- positive metastatic breast cancer.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
曲妥珠单抗deruxtecan治疗成人her2阳性乳腺癌患者
2020年,波兰约有1.8万名妇女被诊断患有乳腺癌,其中6000人死亡。近年来,我们在乳腺癌患者的诊断和治疗方面取得了重大进展。如果早期发现并适当治疗,预后非常好,甚至一些远处转移的患者也能长期生存。最常见的生物学亚型是激素受体阳性乳腺癌,约占诊断的70%,表现为雌激素和孕激素受体的表达。三阴性乳腺癌和her2阳性乳腺癌各占所有病例的15%左右。在晚期her2阳性乳腺癌的治疗中,一线使用多西他赛联合帕妥珠单抗和曲妥珠单抗。在随后的治疗中,选择包括曲妥珠单抗德鲁西替康(T-DXd)、曲妥珠单抗恩坦辛、拉帕替尼、图卡替尼、玛吉妥昔单抗和曲妥珠单抗。曲妥珠单抗是一种免疫偶联物,一旦进入细胞,就会释放一种细胞抑制剂,破坏其遗传物质和邻近细胞(“旁观者效应”)。与二线及后续治疗中使用的标准治疗相比,它显著延长了疾病进展的时间和总体生存期。它代表了早期HER2阳性转移性乳腺癌患者的有效和有价值的治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.90
自引率
20.00%
发文量
46
审稿时长
15 weeks
期刊最新文献
Immunochemotherapy in patients with non-squamous lung cancer Chemotherapy in patients with testicular germ-cell tumors and end-stage renal disease requiring hemodialysis: two case reports Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index as clinical predictive and prognostic markers in patients with advanced pancreatic cancer receiving gemcitabine monotherapy Systemic treatment in triple-negative breast cancer patients — standard and novel approaches Tumor heterogeneity and its impact on sotorasib response in a patient with non-small cell lung cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1